| |
Pre-Clinical |
Clinical* |
|
| |
Lead Optimization |
IND Enabling |
IND Filing |
Phase 1 |
Phase 2 |
Phase 3 |
Market |
PV-10
Melanoma |
- Second End-of-Phase 2 FDA meeting March 2011
- Phase 2 study completed May 2010
- End-of-Phase 2 FDA meeting April 2010
- Phase 2 treatments completed September 2009
- Phase 2 recruitment completed May 2009
- Phase 2 study initiated Sep 2007
- Orphan drug status Jan 2007
|
PH-10
Psoriasis |
- Phase 2c study completed Aug 2011
- Phase 2c randomized study initiated Dec 2010
- Phase 2 study completed Apr 2010
- Phase 2 recruitment completed Oct 2009
- Replacement Phase 2 initiated Jul 2009 due to dose regimen change
- Phase 2 study initiated Nov 2007
|
PH-10
Atopic Dermatitis |
- Phase 2 study completed Sep 2009
- Phase 2 recruitment completed Jun 2009
- Phase 2 study initiated Jun 2008
|
PV-10
Breast Cancer |
- Phase 1 study completed Jul 2008
- Phase 1 initial cohort treatment completed April 2006
- Phase 1 study initiated October 2005
|
PV-10
Liver Metastasis |
- Orphan drug status Apr 2011
- Phase 1 patient accrual and treatment completed Jan 2011
- Phase 1 study initiated Oct 2009
|
